6.265 USD
+0.36 (+6.19%)
We assign a fundamental rating of 3 out of 10 to ARDX. ARDX was compared to 531 industry peers in the Biotechnology industry. ARDX has a bad profitability rating. Also its financial health evaluation is rather negative. ARDX is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year ARDX has reported negative net income.
ARDX had a negative operating cash flow in the past year.
In the past 5 years ARDX always reported negative net income.
In the past 5 years ARDX always reported negative operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of -11.63%, ARDX belongs to the best of the industry, outperforming 83.24% of the companies in the same industry.
ARDX has a better Return On Equity (-36.65%) than 72.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.63% | ||
| ROE | -36.65% | ||
| ROIC | N/A |
ROA(3y)-22.18%
ROA(5y)-43.77%
ROE(3y)-43.52%
ROE(5y)-79.37%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of ARDX (88.21%) is better than 90.21% of its industry peers.
ARDX's Gross Margin has been stable in the last couple of years.
ARDX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.21% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y-0.87%
2. Health
2.1 Basic Checks
ARDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ARDX has more shares outstanding
ARDX has more shares outstanding than it did 5 years ago.
ARDX has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 1.13, we must say that ARDX is in the distress zone and has some risk of bankruptcy.
ARDX's Altman-Z score of 1.13 is fine compared to the rest of the industry. ARDX outperforms 61.77% of its industry peers.
ARDX has a Debt/Equity ratio of 1.31. This is a high value indicating a heavy dependency on external financing.
ARDX has a Debt to Equity ratio of 1.31. This is in the lower half of the industry: ARDX underperforms 78.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.31 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.13 |
ROIC/WACCN/A
WACC8.79%
2.3 Liquidity
ARDX has a Current Ratio of 4.41. This indicates that ARDX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ARDX (4.41) is comparable to the rest of the industry.
ARDX has a Quick Ratio of 4.11. This indicates that ARDX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.11, ARDX is in line with its industry, outperforming 50.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.41 | ||
| Quick Ratio | 4.11 |
3. Growth
3.1 Past
ARDX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.09%, which is quite impressive.
ARDX shows a strong growth in Revenue. In the last year, the Revenue has grown by 58.12%.
The Revenue has been growing by 129.15% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)24.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)58.12%
Revenue growth 3Y220.85%
Revenue growth 5Y129.15%
Sales Q2Q%12.3%
3.2 Future
ARDX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 52.30% yearly.
The Revenue is expected to grow by 21.61% on average over the next years. This is a very strong growth
EPS Next Y-47.68%
EPS Next 2Y72.13%
EPS Next 3Y81.14%
EPS Next 5Y52.3%
Revenue Next Year22.14%
Revenue Next 2Y24.94%
Revenue Next 3Y25.4%
Revenue Next 5Y21.61%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
ARDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 39.91, which means the current valuation is very expensive for ARDX.
Based on the Price/Forward Earnings ratio, ARDX is valued cheaply inside the industry as 91.53% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 23.96. ARDX is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 39.91 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ARDX's earnings are expected to grow with 81.14% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y72.13%
EPS Next 3Y81.14%
5. Dividend
5.1 Amount
No dividends for ARDX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:ARDX (12/12/2025, 2:53:03 PM)
6.265
+0.36 (+6.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners67.03%
Inst Owner Change-11.13%
Ins Owners2.41%
Ins Owner Change2.48%
Market Cap1.52B
Revenue(TTM)398.23M
Net Income(TTM)-56.55M
Analysts88.24
Price Target11.83 (88.83%)
Short Float %7.88%
Short Ratio5.22
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)70.63%
Min EPS beat(2)41.25%
Max EPS beat(2)100%
EPS beat(4)3
Avg EPS beat(4)104.52%
Min EPS beat(4)-46.66%
Max EPS beat(4)323.5%
EPS beat(8)6
Avg EPS beat(8)68.73%
EPS beat(12)9
Avg EPS beat(12)555.37%
EPS beat(16)12
Avg EPS beat(16)418.32%
Revenue beat(2)2
Avg Revenue beat(2)12.32%
Min Revenue beat(2)6.56%
Max Revenue beat(2)18.08%
Revenue beat(4)3
Avg Revenue beat(4)5.1%
Min Revenue beat(4)-7.8%
Max Revenue beat(4)18.08%
Revenue beat(8)6
Avg Revenue beat(8)10.55%
Revenue beat(12)10
Avg Revenue beat(12)30.4%
Revenue beat(16)13
Avg Revenue beat(16)26.24%
PT rev (1m)3.74%
PT rev (3m)3.74%
EPS NQ rev (1m)96.42%
EPS NQ rev (3m)180.99%
EPS NY rev (1m)23.73%
EPS NY rev (3m)33.54%
Revenue NQ rev (1m)2.56%
Revenue NQ rev (3m)5.76%
Revenue NY rev (1m)3.2%
Revenue NY rev (3m)5.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 39.91 | ||
| P/S | 3.82 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 9.87 | ||
| P/tB | 9.87 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.23
EYN/A
EPS(NY)0.16
Fwd EY2.51%
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS1.64
BVpS0.63
TBVpS0.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.63% | ||
| ROE | -36.65% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.21% | ||
| FCFM | N/A |
ROA(3y)-22.18%
ROA(5y)-43.77%
ROE(3y)-43.52%
ROE(5y)-79.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y-0.87%
F-Score5
Asset Turnover0.82
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.31 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 64.96% | ||
| Cap/Sales | 0.43% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.41 | ||
| Quick Ratio | 4.11 | ||
| Altman-Z | 1.13 |
F-Score5
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)26.96%
Cap/Depr(5y)45.67%
Cap/Sales(3y)0.23%
Cap/Sales(5y)4.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y-47.68%
EPS Next 2Y72.13%
EPS Next 3Y81.14%
EPS Next 5Y52.3%
Revenue 1Y (TTM)58.12%
Revenue growth 3Y220.85%
Revenue growth 5Y129.15%
Sales Q2Q%12.3%
Revenue Next Year22.14%
Revenue Next 2Y24.94%
Revenue Next 3Y25.4%
Revenue Next 5Y21.61%
EBIT growth 1Y41.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year5.98%
EBIT Next 3Y105.48%
EBIT Next 5Y73.54%
FCF growth 1Y18.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.19%
OCF growth 3YN/A
OCF growth 5YN/A
ARDELYX INC / ARDX FAQ
What is the ChartMill fundamental rating of ARDELYX INC (ARDX) stock?
ChartMill assigns a fundamental rating of 3 / 10 to ARDX.
What is the valuation status for ARDX stock?
ChartMill assigns a valuation rating of 2 / 10 to ARDELYX INC (ARDX). This can be considered as Overvalued.
How profitable is ARDELYX INC (ARDX) stock?
ARDELYX INC (ARDX) has a profitability rating of 2 / 10.